Antithrombotic “in vivo” effects of quercetin 3,7,3’,4’-tetrasulfate isolated from Flaveria bidentis in an experimental thrombosis model in mice

GUGLIELMONE, HUGO A.; AGNESE, ALICIA M.; NUÑEZ-MONTOYA, SUSANA C.; CABRERA, JOSÉ L.; CUADRA, GABRIEL R.

THROMBOSIS RESEARCH

PERGAMON-ELSEVIER SCIENCE LTD

Año: 2020 vol. 195 p. 190 - 190

0049-3848

hrombotic events are the major causes of morbidity and mortality worldwide, with venous thromboembolism, heart attack and strokes being responsible for one in every four deaths. Effective antithrombotic therapy has long been the basis of treatment for venous/arterial thromboembolic events and has reduced mortality rates from 30% to 3-8%. Currently, there are many antithrombotic agents that can selectively interrupt pathological thrombin generation and the exaggerated platelet response, thus preventing the consequent thrombosis. Plants are abundant sources of novel bioactive compounds and, in particular flavonoids, a large group of naturally occurring compounds isolated from certain plants, have been found to inhibit thrombus formation. This effect is most evident in compounds that contain a quercetin backbone. Flaveria bidentis (L.) Kuntze, among others, biosynthesizes quercetin 3,7,3?,4?-tetrasulfate isolated (QTS) and quercetin quercetin 3-acetyl-7,3?,4?-trisulfate (ATS), the querce